Guideline-compliant use of albumin - a multicenter retrospective status quo analysis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00035894

Enrollment

600

Registered

2025-01-14

Start date

2024-12-02

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analysis of the active substance albumin according to ATC B05AA01

Interventions

Group 1: For patients who received albumin in 2023, it will be assessed whether the administration of albumin was in compliance with guidelines.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patient in the above-mentioned clinics in the period of the year 2023; patient has received at least one dose of albumin during the study period

Exclusion criteria

Exclusion criteria: Age under 18 years

Design outcomes

Primary

Measure	Time frame
Percentage of patients who received a guideline-compliant first dose of albumin in 2023	—

Secondary

Measure	Time frame
Percentage of patients who received a guideline-compliant dosage of albumin in 2023	—

Countries

Germany

Contacts

Public ContactSimone Eisenhofer

EKK plus GmbH

eisenhofer@gdekk.de+49 221 / 340 399-74

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026